Summit Therapeutics IncNASDAQ:SMMT
- LAST PRICE4.3900
- TODAY'S CHANGE (%)0.3300 (8.1281%)
- Bid / Lots4.3700/ 1
- Ask / Lots4.4100/ 30
- Open / Previous Close4.0800 / 4.0600
- Day Range
- 52 Week Range
- Volume1,862,563
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SMMT |
|---|---|---|
| 09:32 ET | 32345 | 4.2376 |
| 09:34 ET | 18664 | 4.3 |
| 09:36 ET | 23898 | 4.3 |
| 09:38 ET | 14706 | 4.28 |
| 09:39 ET | 5938 | 4.19 |
| 09:41 ET | 13300 | 4.1301 |
| 09:43 ET | 4970 | 4.13 |
| 09:45 ET | 13331 | 4.0795 |
| 09:48 ET | 59310 | 4.17 |
| 09:50 ET | 6399 | 4.195 |
| 09:52 ET | 8262 | 4.255 |
| 09:54 ET | 4447 | 4.245 |
| 09:56 ET | 10800 | 4.245 |
| 09:57 ET | 13176 | 4.245 |
| 09:59 ET | 22552 | 4.24 |
| 10:01 ET | 2391 | 4.245 |
| 10:03 ET | 23561 | 4.3 |
| 10:06 ET | 25575 | 4.395 |
| 10:08 ET | 10600 | 4.355 |
| 10:10 ET | 9375 | 4.345 |
| 10:12 ET | 638 | 4.35 |
| 10:14 ET | 5074 | 4.325 |
| 10:15 ET | 10754 | 4.42 |
| 10:17 ET | 10478 | 4.4097 |
| 10:19 ET | 5242 | 4.345 |
| 10:21 ET | 3690 | 4.39 |
| 10:24 ET | 14748 | 4.385 |
| 10:26 ET | 2118 | 4.385 |
| 10:28 ET | 9587 | 4.435 |
| 10:30 ET | 6786 | 4.4272 |
| 10:32 ET | 6677 | 4.455 |
| 10:33 ET | 24839 | 4.455 |
| 10:35 ET | 1800 | 4.455 |
| 10:37 ET | 86639 | 4.4501 |
| 10:39 ET | 14227 | 4.425 |
| 10:42 ET | 13706 | 4.4401 |
| 10:44 ET | 13470 | 4.405 |
| 10:46 ET | 3689 | 4.445 |
| 10:48 ET | 2565 | 4.405 |
| 10:50 ET | 3500 | 4.425 |
| 10:51 ET | 5326 | 4.44 |
| 10:53 ET | 400 | 4.435 |
| 10:55 ET | 4295 | 4.475 |
| 10:57 ET | 8396 | 4.48 |
| 11:00 ET | 1606 | 4.455 |
| 11:02 ET | 1585 | 4.4506 |
| 11:04 ET | 2889 | 4.46 |
| 11:06 ET | 6701 | 4.41 |
| 11:08 ET | 1202 | 4.4105 |
| 11:09 ET | 6400 | 4.365 |
| 11:11 ET | 6621 | 4.365 |
| 11:13 ET | 5433 | 4.345 |
| 11:15 ET | 3551 | 4.345 |
| 11:18 ET | 21443 | 4.345 |
| 11:20 ET | 23598 | 4.35 |
| 11:22 ET | 700 | 4.345 |
| 11:24 ET | 32410 | 4.335 |
| 11:26 ET | 1050 | 4.34 |
| 11:27 ET | 4259 | 4.37 |
| 11:29 ET | 4900 | 4.4 |
| 11:31 ET | 5612 | 4.415 |
| 11:33 ET | 1400 | 4.415 |
| 11:36 ET | 19412 | 4.36 |
| 11:38 ET | 10253 | 4.35 |
| 11:40 ET | 1309 | 4.385 |
| 11:42 ET | 3050 | 4.39 |
| 11:44 ET | 3768 | 4.405 |
| 11:45 ET | 2142 | 4.4 |
| 11:47 ET | 300 | 4.4 |
| 11:49 ET | 1551 | 4.405 |
| 11:51 ET | 1883 | 4.39 |
| 11:54 ET | 1600 | 4.4 |
| 11:56 ET | 11346 | 4.39 |
| 11:58 ET | 7900 | 4.375 |
| 12:00 ET | 600 | 4.38 |
| 12:02 ET | 1906 | 4.395 |
| 12:03 ET | 6088 | 4.36 |
| 12:05 ET | 6817 | 4.3505 |
| 12:07 ET | 683 | 4.355 |
| 12:09 ET | 16502 | 4.345 |
| 12:12 ET | 12588 | 4.36 |
| 12:14 ET | 5341 | 4.37 |
| 12:16 ET | 16211 | 4.36 |
| 12:18 ET | 3927 | 4.36 |
| 12:20 ET | 900 | 4.365 |
| 12:21 ET | 3633 | 4.385 |
| 12:23 ET | 714 | 4.39 |
| 12:25 ET | 2800 | 4.395 |
| 12:27 ET | 758 | 4.4 |
| 12:30 ET | 700 | 4.4 |
| 12:32 ET | 4195 | 4.375 |
| 12:34 ET | 800 | 4.375 |
| 12:36 ET | 3742 | 4.365 |
| 12:38 ET | 300 | 4.365 |
| 12:39 ET | 100 | 4.365 |
| 12:41 ET | 5203 | 4.395 |
| 12:43 ET | 368 | 4.395 |
| 12:45 ET | 548 | 4.395 |
| 12:48 ET | 322 | 4.4 |
| 12:50 ET | 2700 | 4.399 |
| 12:52 ET | 900 | 4.395 |
| 12:54 ET | 300 | 4.395 |
| 12:56 ET | 772 | 4.3907 |
| 12:57 ET | 1700 | 4.395 |
| 12:59 ET | 3562 | 4.365 |
| 01:01 ET | 1509 | 4.39 |
| 01:03 ET | 1600 | 4.3896 |
| 01:06 ET | 4707 | 4.36 |
| 01:08 ET | 600 | 4.365 |
| 01:10 ET | 100 | 4.365 |
| 01:12 ET | 100 | 4.365 |
| 01:14 ET | 3600 | 4.365 |
| 01:15 ET | 700 | 4.365 |
| 01:17 ET | 2484 | 4.38 |
| 01:19 ET | 100 | 4.39 |
| 01:21 ET | 1755 | 4.3789 |
| 01:24 ET | 200 | 4.375 |
| 01:26 ET | 7721 | 4.365 |
| 01:28 ET | 511 | 4.365 |
| 01:30 ET | 400 | 4.36 |
| 01:32 ET | 400 | 4.3602 |
| 01:33 ET | 2500 | 4.365 |
| 01:35 ET | 11451 | 4.37 |
| 01:37 ET | 4100 | 4.38 |
| 01:39 ET | 17098 | 4.39 |
| 01:42 ET | 12127 | 4.4 |
| 01:44 ET | 11888 | 4.3601 |
| 01:48 ET | 1700 | 4.3601 |
| 01:50 ET | 600 | 4.3614 |
| 01:51 ET | 100 | 4.365 |
| 01:53 ET | 4300 | 4.365 |
| 01:55 ET | 500 | 4.365 |
| 01:57 ET | 200 | 4.365 |
| 02:00 ET | 400 | 4.365 |
| 02:02 ET | 6022 | 4.3675 |
| 02:04 ET | 400 | 4.365 |
| 02:06 ET | 433 | 4.365 |
| 02:08 ET | 1586 | 4.365 |
| 02:09 ET | 2293 | 4.3606 |
| 02:11 ET | 1805 | 4.365 |
| 02:13 ET | 500 | 4.365 |
| 02:15 ET | 1158 | 4.3638 |
| 02:18 ET | 43372 | 4.385 |
| 02:20 ET | 214 | 4.385 |
| 02:22 ET | 100 | 4.39 |
| 02:24 ET | 1078 | 4.39 |
| 02:26 ET | 100 | 4.385 |
| 02:27 ET | 1826 | 4.385 |
| 02:29 ET | 500 | 4.385 |
| 02:31 ET | 2900 | 4.385 |
| 02:33 ET | 1000 | 4.385 |
| 02:36 ET | 13739 | 4.355 |
| 02:38 ET | 26785 | 4.33 |
| 02:40 ET | 1048 | 4.335 |
| 02:42 ET | 2599 | 4.35 |
| 02:44 ET | 1980 | 4.3575 |
| 02:45 ET | 1300 | 4.36 |
| 02:47 ET | 700 | 4.355 |
| 02:49 ET | 3285 | 4.345 |
| 02:51 ET | 2100 | 4.345 |
| 02:54 ET | 10706 | 4.335 |
| 02:56 ET | 400 | 4.335 |
| 02:58 ET | 2498 | 4.335 |
| 03:00 ET | 1305 | 4.335 |
| 03:02 ET | 800 | 4.335 |
| 03:03 ET | 4147 | 4.335 |
| 03:05 ET | 1207 | 4.335 |
| 03:07 ET | 1560 | 4.335 |
| 03:09 ET | 13811 | 4.38 |
| 03:12 ET | 17403 | 4.375 |
| 03:14 ET | 23282 | 4.405 |
| 03:16 ET | 2600 | 4.41 |
| 03:18 ET | 14373 | 4.365 |
| 03:20 ET | 4978 | 4.3601 |
| 03:21 ET | 9981 | 4.345 |
| 03:23 ET | 200 | 4.345 |
| 03:25 ET | 1800 | 4.345 |
| 03:27 ET | 8529 | 4.345 |
| 03:30 ET | 1352 | 4.345 |
| 03:32 ET | 2200 | 4.345 |
| 03:34 ET | 9206 | 4.345 |
| 03:36 ET | 2458 | 4.345 |
| 03:38 ET | 1500 | 4.345 |
| 03:39 ET | 1400 | 4.345 |
| 03:41 ET | 1934 | 4.345 |
| 03:43 ET | 3520 | 4.345 |
| 03:45 ET | 3128 | 4.345 |
| 03:48 ET | 5518 | 4.35 |
| 03:50 ET | 5907 | 4.345 |
| 03:52 ET | 23778 | 4.37 |
| 03:54 ET | 30504 | 4.385 |
| 03:56 ET | 53504 | 4.385 |
| 03:57 ET | 51551 | 4.385 |
| 03:59 ET | 275922 | 4.39 |
May 1, 2024
*DJ Summit Therapeutics 1Q Loss/Shr 6c >SMMT, from 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
7:00AM ET on Wednesday May 01, 2024 by Dow JonesSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024, from 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
7:00AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 24, 2024
Press Release: Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024, from 4:46PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:46PM ET on Wednesday Apr 24, 2024 by Dow JonesSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024, from 4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 11, 2024
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors, from 4:30PM ET on Thursday Apr 11, 2024 by Dow Jones
4:30PM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Summit Therapeutics Inc | 2.9B | -2.9x | --- |
Apogee Therapeutics Inc | 2.9B | -31.2x | --- |
MoonLake Immunotherapeutics | 2.7B | -59.4x | --- |
Celldex Therapeutics Inc | 2.7B | -14.6x | --- |
CG Oncology Inc | 2.6B | -34.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Contact Information
- Headquarters
- 2882 Sand Hill Road, Suite 106MENLO PARK, CA, United States 94025
- Phone
- 650-460-8308
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Chief Executive Officer
- Robert Duggan
- President, Co-Chief Executive Officer, Director
- Mahkam Zanganeh
- Chief Financial Officer
- Ankur Dhingra
- Chief Operating Officer, Director
- Manmeet Soni
- Lead Non-Executive Independent Director
- Kenneth Clark
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.28 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
